Methimazole (Tapazole) Medicare Part D Coverage

How Medicare Part D Covers Methimazole

Most Medicare Part D plans place generic methimazole on their preferred generic tier, which means the lowest possible copay. Because the drug's wholesale acquisition cost falls below $50 per month, it qualifies for preferred generic status under the standard Part D benefit design established by the Centers for Medicare & Medicaid Services (CMS) 1.

Part D coverage works through four cost-sharing phases: deductible, initial coverage, coverage gap, and catastrophic coverage. For a drug priced at roughly $15, most beneficiaries never reach meaningful out-of-pocket exposure. Plans that waive the deductible for Tier 1 drugs (a common practice in 2026) allow enrollees to pay only a flat copay from their first fill.

The American Thyroid Association (ATA) recommends methimazole as first-line therapy for Graves' disease in most non-pregnant adults 2. This guideline endorsement contributes to its broad formulary inclusion. Dr. Douglas Ross, co-author of the 2016 ATA hyperthyroidism guidelines, has stated: "Methimazole is preferred over propylthiouracil for virtually all patients who choose antithyroid drug therapy, except during the first trimester of pregnancy." This preference for methimazole over propylthiouracil (PTU) is reflected in Part D formulary design, where methimazole appears on lower tiers than PTU on many plans.

Prior authorization is not required for methimazole on any major Part D plan. Quantity limits, when present, typically cap at 90 tablets per 30 days, a threshold that accommodates even high-dose regimens for severe thyrotoxicosis.

What You Will Pay Out of Pocket

Your actual copay depends on your specific Part D plan, but the range is narrow. Tier 1 copays across standalone Part D plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) average between $1 and $11 for preferred generics in 2026, according to CMS plan finder data 3.

Here is what a typical cost breakdown looks like across plan types:

For standalone PDPs, expect $0 to $10 per fill. For MA-PDs with integrated drug benefits, copays run $0 to $15. Plans with $0 deductible for generics charge only the copay from fill one. Plans with a standard deductible ($590 in 2026) may require full price until the deductible is met, but at $15, even that payment is modest.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully implemented in 2025, means methimazole costs count toward a ceiling that protects high-utilizers of other medications 4. For a beneficiary taking only methimazole, the annual drug cost ($180 at full cash price, less with insurance) stays far below this threshold.

Beneficiaries enrolled in the Medicare Part D Extra Help (Low-Income Subsidy) program pay $0 for generic methimazole in most cases. Over 13 million Medicare beneficiaries qualified for Extra Help in 2024, according to CMS enrollment data 5.

Generic vs. Brand: Why Tapazole Is Almost Never Dispensed

Brand-name Tapazole, originally manufactured by Pfizer (later King Pharmaceuticals, then Pfizer again through acquisition), has been off-patent for decades. The FDA's Orange Book lists multiple approved ANDA holders for methimazole 5 mg and 10 mg tablets, all rated AB (therapeutically equivalent) to the reference listed drug 6.

Pharmacies rarely stock brand Tapazole. The brand price, when available, exceeds $200 for 30 tablets. No rational coverage scenario exists where a Part D plan would cover brand Tapazole at a lower copay than the generic. If your pharmacy attempts to dispense the brand, request the generic substitution. Every U.S. state permits generic substitution for AB-rated drugs unless the prescriber writes "Dispense as Written" (DAW), and even then, most Part D plans impose a penalty copay on brand-when-generic-is-available dispensing.

The FDA's position on generic drug equivalence is direct. Per the agency's guidance: "FDA-approved generic drugs have met rigorous standards for pharmaceutical equivalence and bioequivalence, meaning they work the same way and provide the same clinical benefit as their brand-name counterparts" 7.

How to Check Your Specific Plan's Formulary

Not all Part D plans are identical. Verify methimazole coverage before your next fill using these steps.

Log into Medicare Plan Finder and enter your ZIP code and current medications. The tool displays the tier placement, copay, and any restrictions for methimazole on every plan available in your area. You can also call the number on the back of your Part D card and ask for formulary confirmation.

If you are comparing plans during Open Enrollment (October 15 through December 7), check whether a plan waives the deductible for Tier 1 generics. This single feature determines whether you pay $15 or $1 at your first January fill. Plans change formularies annually, so do not assume this year's coverage mirrors last year's.

For beneficiaries already enrolled in a plan, the Summary of Benefits document (mailed each September) lists copay amounts by tier. Your plan's online formulary search tool provides real-time status including any mid-year formulary changes, which CMS permits with 60-day advance notice 8.

When Medicare Does Not Cover Methimazole

Original Medicare (Parts A and B) does not cover outpatient prescription drugs. Methimazole is an oral tablet taken at home, so it falls outside Part B's limited drug benefit (which covers only physician-administered injectables and a small list of oral cancer and immunosuppressive drugs). You must have Part D or a Medicare Advantage plan with drug coverage to receive insurance benefits for methimazole.

Two narrow exceptions exist. If you are admitted as a hospital inpatient (Part A), methimazole administered during your stay is covered under the hospital's DRG payment. If you receive methimazole as part of outpatient observation or an emergency department visit billed under Part B, the facility may include it in the outpatient payment bundle, but you would still need Part D for your discharge prescription.

Beneficiaries without Part D face the full cash price. At $15 or less for generic methimazole, the financial impact is small relative to most prescription drugs. This is one of the rare scenarios where going uninsured for a specific drug costs less than many Part D monthly premiums (which average $46.50 in 2026) 9.

Savings Programs Beyond Medicare

Several pathways exist to reduce methimazole costs below the already-low baseline.

Pharmacy discount cards and GoodRx. Generic methimazole is frequently priced at $4 to $10 through discount card programs at major chain pharmacies. Walmart, Costco, and several grocery-chain pharmacies include methimazole on their $4 generic lists. These prices may beat your Part D copay. One important note: payments made with discount cards do not count toward your Part D deductible or out-of-pocket maximum, so weigh total annual spending before bypassing insurance.

Mark Cuban Cost Plus Drugs. This direct-to-consumer pharmacy lists methimazole at cost-plus markup, typically resulting in prices under $10 for a 90-day supply. Again, these purchases bypass Part D cost-sharing accumulators.

State pharmaceutical assistance programs (SPAPs). Twenty-three states operate SPAPs that supplement Medicare Part D for low-income seniors. Eligibility varies by state, but many cover Part D copays and premiums for beneficiaries between 150% and 300% of the federal poverty level 10.

Extra Help / Low-Income Subsidy. If your annual income falls below approximately $22,590 (individual) or $30,660 (couple) in 2026, you may qualify for Extra Help, which reduces Part D premiums, eliminates deductibles, and caps generic copays at $4.50 or $0 depending on subsidy level. Apply through the Social Security Administration or your State Health Insurance Assistance Program (SHIP) 11.

Manufacturer coupons. Because methimazole is available only as a generic (brand Tapazole is functionally discontinued from the market), no manufacturer coupon program exists. Pfizer does not operate a patient assistance program for Tapazole. Generic drug manufacturers do not typically offer copay cards. This is rarely a barrier given the drug's already minimal cost.

Methimazole Dosing and How It Affects Quantity Covered

Medicare Part D covers methimazole at all FDA-approved doses, but quantity limits may affect fills for high-dose regimens. Most plans permit up to 90 tablets per 30-day fill without prior authorization.

The ATA guidelines recommend initial methimazole dosing based on disease severity: 5 to 10 mg daily for mild hyperthyroidism, 10 to 20 mg daily for moderate disease, and 20 to 40 mg daily for severe thyrotoxicosis 2. A patient on 30 mg daily (three 10 mg tablets) would need 90 tablets per month, hitting the typical quantity limit. Patients on 40 mg daily may require a prior authorization or exception request, though this is uncommon.

Maintenance dosing, typically 5 to 10 mg daily after 4 to 8 weeks of initial therapy, falls well within standard quantity limits. Long-term low-dose methimazole therapy (2.5 to 5 mg daily) for 12 to 18 months is a standard approach in Graves' disease before considering definitive therapy with radioactive iodine or surgery 12.

A retrospective study of 302 patients with Graves' disease found that low-dose methimazole maintenance (median 5 mg daily) for 60 to 120 months produced remission rates of 61.5%, compared to 41.8% in patients treated for the conventional 12 to 18 months 13. This supports the trend toward longer antithyroid drug courses, meaning patients may need Part D coverage for methimazole for several years.

Comparing Methimazole to Other Hyperthyroidism Treatments Under Part D

Methimazole is not the only medication used for hyperthyroidism, but it is the most cost-effective option covered by Part D.

Propylthiouracil (PTU), the other available antithyroid drug, is also generic and similarly inexpensive ($10 to $25 for a 30-day supply). PTU carries a higher risk of hepatotoxicity, and the FDA issued a black box warning in 2010 14. Part D plans cover PTU, but it is reserved for first-trimester pregnancy and thyroid storm.

Beta-blockers (propranolol, atenolol) used for symptom control in hyperthyroidism are Tier 1 generics on virtually all Part D plans, with copays comparable to methimazole. These are adjunctive, not definitive, therapy.

Radioactive iodine (I-131) therapy is covered under Part B as a physician-administered treatment, not Part D. Thyroid surgery is also a Part A/B benefit. Neither requires Part D coverage, but both result in permanent hypothyroidism requiring lifelong levothyroxine (another Tier 1 generic, $4 to $10 per month).

Dr. Elizabeth Pearce, an endocrinologist at Boston Medical Center and former president of the American Thyroid Association, has noted: "The choice between antithyroid drugs, radioactive iodine, and surgery should be individualized based on patient preference, disease severity, and clinical context." For patients who choose antithyroid drug therapy, methimazole's low cost under Part D removes financial barriers to adherence.

Monitoring Costs Covered by Medicare Part B

Methimazole therapy requires regular lab monitoring that falls under Part B, not Part D. TSH and free T4 levels are typically checked every 4 to 6 weeks during dose titration and every 3 to 6 months during maintenance 2. Complete blood counts (CBC) should be checked at baseline and if symptoms of agranulocytosis develop (fever, sore throat).

Part B covers diagnostic lab work at 100% with no copay when ordered by a Medicare-enrolled provider and performed by a Medicare-participating laboratory. This is a significant financial benefit. The agranulocytosis risk with methimazole (0.2% to 0.5% incidence) requires patient education but not routine serial CBC monitoring per ATA guidelines 15.

Liver function tests at baseline are recommended because methimazole can cause cholestatic hepatotoxicity, though this is far less common than PTU-related hepatocellular injury. Part B covers these labs without patient cost-sharing at Medicare-participating facilities.

Switching Plans During Open Enrollment

If your current Part D plan charges more than $10 for methimazole, you may be overpaying. During the Annual Enrollment Period (October 15 to December 7), compare plans using the Medicare Plan Finder tool. Enter methimazole along with all your other medications, your preferred pharmacy, and your ZIP code. The tool ranks plans by total estimated annual cost, not just monthly premium.

For beneficiaries whose only chronic medication is methimazole, the lowest-premium Part D plan is often the best value. A plan with a $0 premium and $5 generic copay produces annual methimazole costs of $60. A plan with a $25 premium and $0 generic copay costs $300 in premiums alone. Run the numbers for your full medication list before switching.

Medicare Advantage plans with built-in drug coverage (MA-PDs) may bundle methimazole copays with other benefits like dental and vision. If you are healthy aside from hyperthyroidism, a high-deductible MA-PD with low drug copays could save money overall. SHIP counselors in every state provide free, unbiased help with plan comparisons 16.